Literature DB >> 12658903

[Generic drugs--medical progress at a moderate price].

Markus Müller.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 12658903     DOI： 10.1007/BF03040264

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN： 0043-5325            Impact factor:   1.704


× No keyword cloud information.
  3 in total

1.  [Cost reduction with project based prescription of generic ACE inhibitors].

Authors:  Michael Wolzt; Gerald Ohrenberger; Berthold Reichardt
Journal:  Wien Klin Wochenschr       Date:  2003-01-31       Impact factor: 1.704

2.  How drug prices are set: an example from the perspective of a social security association.

Authors:  Hans-Georg Eichler; Anna Bucsics; Peter Wieninger
Journal:  Clin Pharmacol Ther       Date:  2002-07       Impact factor: 6.875

3.  Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.

Authors:  Sebastian Schneeweiss; Alexander M Walker; Robert J Glynn; Malcolm Maclure; Colin Dormuth; Stephen B Soumerai
Journal:  N Engl J Med       Date:  2002-03-14       Impact factor: 91.245
  3 in total
  2 in total

1.  [Partial reimbursement of prescription charges for generic drugs reduces costs for both health insurance and patients].

Authors:  Ghazaleh Gouya; Berthold Reichardt; Anja Bidner; Robert Weissenfels; Michael Wolzt
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

2.  [Generics in Austria 2003-2008: an update].

Authors:  Markus Müller
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.